Halozyme Therapeutics Inc’s filing revealed that its Director Henderson Jeffrey William unloaded Company’s shares for reported $0.27 million on Apr 28 ’25. In the deal valued at $60.37 per share,4,497 shares were sold. As a result of this transaction, Henderson Jeffrey William now holds 28,611 shares worth roughly $1.55 million.
Then, Henderson Jeffrey William sold 503 shares, generating $32,217 in total proceeds. Upon selling the shares at $64.05, the Director now owns 33,108 shares.
Before that, Henderson Jeffrey William sold 5,000 shares. Halozyme Therapeutics Inc shares valued at $293,458 were divested by the Director at a price of $58.69 per share. As a result of the transaction, Henderson Jeffrey William now holds 33,611 shares, worth roughly $1.83 million.
Morgan Stanley downgraded its Halozyme Therapeutics Inc [HALO] rating to an Equal-weight from a an Overweight in a research note published recently. A number of analysts have revised their coverage, including Leerink Partners’s analysts, who decreased its forecast for the stock in mid May from “a Market perform” to “an Underperform”. Wells Fargo also remained covering HALO and has decreased its forecast on October 07, 2024 with a “an Equal weight” recommendation from previously “an Overweight” rating. JP Morgan revised its rating on September 19, 2024. It rated HALO as “a Neutral” which previously was an “an Overweight”.
Price Performance Review of HALO
On Friday, Halozyme Therapeutics Inc [NASDAQ:HALO] saw its stock fall -0.09% to $54.33. Over the last five days, the stock has gained 1.91%. Halozyme Therapeutics Inc shares have risen nearly 13.64% since the year began. Nevertheless, the stocks have risen 5.62% over the past one year.
